A
Amir H. Lebastchi
Researcher at University of Southern California
Publications - 74
Citations - 1364
Amir H. Lebastchi is an academic researcher from University of Southern California. The author has contributed to research in topics: Prostate cancer & Prostate. The author has an hindex of 15, co-authored 59 publications receiving 848 citations. Previous affiliations of Amir H. Lebastchi include University of Michigan & Yale University.
Papers
More filters
Journal ArticleDOI
MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis
Michael Ahdoot,Andrew R Wilbur,Sarah E Reese,Amir H. Lebastchi,Sherif Mehralivand,Patrick T. Gomella,Jonathan Bloom,Sandeep Gurram,Minhaj Siddiqui,Paul F. Pinsky,Howard L. Parnes,W. Marston Linehan,Maria Merino,Peter L. Choyke,Joanna H. Shih,Baris Turkbey,Bradford J. Wood,Peter A. Pinto +17 more
TL;DR: Among patients with MRI-visible lesions, combined biopsy led to more detection of all prostate cancers, however, MRI-targeted biopsy alone underestimated the histologic grade of some tumors.
Journal ArticleDOI
The effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease
Seth I. Sokol,Seth I. Sokol,Seth I. Sokol,Vankeepuram S. Srinivas,Vankeepuram S. Srinivas,Jill P. Crandall,Mimi Kim,George Tellides,Amir H. Lebastchi,Yiting Yu,Alok Gupta,Michael H. Alderman +11 more
TL;DR: Repleting vitamin D levels in subjects with CAD failed to demonstrate any benefits on surrogate markers of cardiovascular health, and the role of vitamin D supplementation in modifying cardiovascular disease is questioned.
Journal ArticleDOI
Immune Therapy and β-Cell Death in Type 1 Diabetes
Jasmin Lebastchi,Songyan Deng,Amir H. Lebastchi,Isabel Beshar,Stephen E. Gitelman,Steven M. Willi,Peter A. Gottlieb,Eitan Moshe Akirav,Jeffrey A. Bluestone,Kevan C. Herold +9 more
TL;DR: There are higher rates of β-cell death in patients with recent-onset T1D compared with nondiabetic subjects, and improvement in C-peptide responses with immune intervention is associated with decreased β- cell death.
Journal ArticleDOI
Contemporary treatments in prostate cancer focal therapy
TL;DR: Prostate cancer focal therapy is an attractive option for well-selected patients because of its low complication profile; however, long-term oncologic outcome is still lacking and early recurrence rates are high, limiting the ability of most urologic associations from endorsing its routine use.
Journal ArticleDOI
Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus.
Amir H. Lebastchi,Arvin K. George,Thomas J. Polascik,Jonathan A. Coleman,Jean de la Rosette,Baris Turkbey,Bradford J. Wood,Michael A. Gorin,Abhinav Sidana,Sangeet Ghai,Kae Jack Tay,John F. Ward,Rafael Sanchez-Salas,Berrend G. Muller,Bernard Malavaud,Pierre Mozer,Sebastien Crouzet,Peter L. Choyke,Osamu Ukimura,Ardeshir R. Rastinehad,Peter A. Pinto +20 more
TL;DR: In this paper, the authors present expert opinion on the use of a standardized nomenclature and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer.